Biotechnology

Antengene Enters into a Global Clinical Collaboration with MSD to Evaluate ATG-022 (CLDN18.2 ADC) In Combination with KEYTRUDA® (pembrolizumab)

- ATG-022 is Antengene's CLDN18.2 antibody-drug conjugate; KEYTRUDA® (pembrolizumab) is MSD's anti-PD-1 therapy. SHANGHAI and HONG KONG, May 20, 2025 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biopharmaceutical compa...

2025-05-20 20:00 2160

Minghui Pharmaceutical Announces First Patient Dosed in the Phase Ⅱ Combination Study of PD-1xVEGF Bispecific and TROP-2 ADC in Advanced NSCLC

SHANGHAI, May 20, 2025 /PRNewswire/ -- Minghui Pharmaceutical, a late-stage biopharmaceutical company dedicated to developing transformative therapies in immunology and oncology, today announced that the first patient has been successfully dosed in a Phase Ⅱ clinical trial evaluating the safety a...

2025-05-20 18:18 3382

Ascletis Announces First Participants Dosed in a U.S. Clinical Study Combining Adipose-Targeted, Once-Monthly Injectable Small Molecule THRβ Agonist, ASC47, and Semaglutide for the Treatment of Obesity

- The combination study is designed to evaluate the safety and preliminary efficacy of a single-dose of ultra-long-acting subcutaneously administered ASC47 in combination with four doses of semaglutide (0.5 mg, once-weekly) in participants with obesity. - Asan adipose-targeted, muscle-preserving...

2025-05-20 18:00 2170

BioFlag Showcases Innovative Probiotic Solutions at Vitafoods Europe 2025

BARCELONA, Spain, May 20, 2025 /PRNewswire/ -- BIOFLAG CO.,LTD.(Bioflag), a leading probiotic enterprise located inChina, proudly unveiled its scientifically validated functional probiotic solutions at Vitafoods Europe 2025, drawing high attention from global media.

2025-05-20 18:00 1438

SPOT-MAS Lung: AI-Powered Blood Test Brings New Hope to High-Risk Non-Smokers in Asia

SINGAPORE, May 20, 2025 /PRNewswire/ -- In a bold step toward equitable cancer care,Gene Solutions introduces SPOT-MAS Lung , a next-generation blood-based test powered by artificial intelligence (AI) and multi-omics ...

2025-05-20 10:55 3084

WuXi XDC Received Multiple Awards from 2025 Extel (previously "Institutional Investor") Ranking in Diverse Categories

SHANGHAI, May 19, 2025 /PRNewswire/ -- WuXi XDC Cayman Inc. ("WuXi XDC", stock code: 2268.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO) focused on the bioconjugate market, today announced that the company received multiple top awards- "Best CEO", "Bes...

2025-05-20 09:44 3022

PHASE Scientific Raises US$34 Million Series A Round to Advance Urine-Based Diagnostic Technology for Early Disease Detection

* Largest Series A financing round in Asia's diagnostic technology sector since 2019 underscores strong investor confidence in PHASE Scientific's breakthrough diagnostic technology and growth vision. * Investment to accelerate R&D and commercialization of cutting-edge early disease detection ...

2025-05-20 09:03 2612

Telix at ANZSNM Annual Scientific Meeting 2025

MELBOURNE, Australia, May 20, 2025 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix", "the Company") today announces a strong presence at the 55th Annual Scientific Meeting of the Australian and New Zealand Society of Nuclear Medicine (ANZSNM ASM 2025), to be held in M...

2025-05-20 06:00 2506

Shanton to Present Topline Data from Phase 2b Study with SAP-001 in Refractory Gout Patients at EULAR 2025 Congress

SAP-001 is Shanton's lead investigational compound with First- and Best-in-Class potential in uncontrolled gout SINGAPORE and PRINCETON, N.J., May 19, 2025 /PRNewswire/ -- Shanton Pharma, a clinical-stage biotech company developing a novel treatment for gout, today announced that it will be pre...

2025-05-19 21:00 2230

Porton Advanced Announces Collaboration with Hualong Biological to Accelerate MATC Cell Therapy Development for Solid Tumor Treatment Breakthroughs

SUZHOU, China, May 19, 2025 /PRNewswire/ -- Porton Advanced, a leading contract development and manufacturing organization (CDMO) specializing in advanced therapy medicinal products (ATMPs), is pleased to announce its partnership with Hualong Biological, an innovator in novel cancer therapeutics....

2025-05-19 21:00 2078

TCI Biotech to Unveil New Vision at Vitafoods Europe 2025: CDMO+, High-Absorption Innovation, and 45 Years of Scientific Leadership

BARCELONA, Spain, May 19, 2025 /PRNewswire/ -- TCI Biotech, a global leader in health and wellness innovation, will mark a major milestone at Vitafoods Europe 2025 with a dynamic showcase of its rebranded identity, next-gen CDMO+ model, and advanced nutritional technologies. Located at booth #3G6...

2025-05-19 16:00 1692

Innovent Released 2024 ESG Report, Underscoring Commitment to Sustainable Development and Global Innovation

SAN FRANCISCO and SUZHOU, China, May 19, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune,...

2025-05-19 08:00 3538

2025 EASL Congress Spotlight: CG-0416 Preclinical Data Unveils A Groundbreaking Dual-Action Therapy Targeting Obesity and MASH

——A First-in-Class Hydrolysis-Activated Liver-Targeted THR-β Prodrug Demonstrating A Dual Advantage of Fat Reduction and Muscle Preservation SHANGHAI, May 16, 2025 /PRNewswire/ -- At the European Association for the Study of the Liver (EASL) Annual Congress, CureGene Pharmaceuticals("CureGene") ...

2025-05-17 08:41 3900

SNS812, an innovative siRNA drug from Oneness and Microbio (Shanghai), selected for ATS 2025 oral presentation, demonstrating world-leading clinical outcomes in COVID-19 treatment

TAIPEI, May 16, 2025 /PRNewswire/ -- The broad-spectrum antiviral siRNA drug SNS812, co-developed by Oneness Biotech (4743.TW) and Microbio (Shanghai), has been selected for oral presentation at the prestigious 2025 American Thoracic Society (ATS) International Conference. The presentation will d...

2025-05-16 23:10 4373

Visionary: Pioneering a New Era in Cancer Screening

TORONTO, May 16, 2025 /PRNewswire/ -- Recently, Visionary has achieved a significant breakthrough in the field of early cancer screening and home self - testing technologies, attracting widespread attention from the industry. American Precision Biotech Inc. is a subsidiary of Visionary Holdings. ...

2025-05-16 21:30 2631

Gene Solutions and NEWCL Forge Strategic Partnership to Advance Genetic Testing in Taiwan

NEW TAIPEI CITY, May 16, 2025 /PRNewswire/ -- In a groundbreaking move, Gene Solutions , a leader in prenatal and oncology genetic testing, andNEWCL Biomedical Laboratory , Taiwan's pioneering clinical laboratory with LDTs certification, have joine...

2025-05-16 19:06 3046

Genome & Company's Skincare Brand UIQ Expands into North America with Official Amazon Brand Store Launch

* Official debut signals full-scale entry into global markets * Biome Barrier Cream Mist earns 'Amazon's Choice' designation SEOUL, South Korea, May 16, 2025 /PRNewswire/ -- Genome & Company, a global clinical-stage biotechnology firm, has officially launched its skincare brand UIQ ( www.theui...

2025-05-16 16:00 2468

Xuanzhu Biopharm's Xuanyuening® (BireociclibTablets) Approved for Dual Indications, Bringing Innovative Breakthroughs to Breast Cancer Treatment

HONG KONG, May 15, 2025 /PRNewswire/ -- On May 15, 2025, the latest announcement released by the National Medical Products Administration attracted widespread attention in the oncology community and the pharmaceutical market. Bireociclib tablets (trade name: Xuanyuening®), a Class 1 anti-tumor ne...

2025-05-16 11:57 2081

ArkBio Announces Positive Phase II Results of AK3280 for Treatment of Idiopathic Pulmonary Fibrosis (IPF)

SHANGHAI, May 16, 2025 /PRNewswire/ -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced positive top-line Phase II study results for its novel anti-fibrotic drug AK3280 in treatment of idiopathic pulmonary fibrosis (IPF). The study, led by Professor Huaping Dai of the Departmen...

2025-05-16 09:00 2819

Alamar Biosciences Expands NULISAseq™ CNS Disease Panel 120 with Groundbreaking Blood-Based Brain-Derived pTau Assays

First-of-its-kind panel includes brain-derived pTau217, pTau181, pTau231, and total tau assays to advance neurodegenerative disease research FREMONT, Calif., May 15, 2025 /PRNewswire/ -- Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, tod...

2025-05-15 21:13 2707
1 ... 43444546474849 ... 341